Jiawan Wang, Hao Zhang, Hailong Yuan, Siqi Chen, Ying Yu, Xuan Zhang, Zeyu Gao, Heng Du, Weitao Li, Yaohui Wang, Pengyan Xia, Jun Wang, Moshi Song
The gut microbiome has emerged as a potential target for the treatment of cardiovascular disease. Ischemia/reperfusion (I/R) after myocardial infarction is a serious complication and whether certain gut bacteria can serve as a treatment option remains unclear. Lactobacillus reuteri (L. reuteri) is a well-studied probiotic that can colonize mammals including humans with known cholesterol-lowering properties and anti-inflammatory effects. Here, the prophylactic cardioprotective effects of L. reuteri or its metabolite γ-aminobutyric acid (GABA) against acute ischemic cardiac injury caused by I/R surgery are demonstrated...
March 15, 2024: Advanced Science (Weinheim, Baden-Wurttemberg, Germany)